GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clene Inc (NAS:CLNNW) » Definitions » Inventories, Other

Clene (CLNNW) Inventories, Other : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Clene Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Clene's other inventories for the quarter that ended in Mar. 2024 was $0.00 Mil.

Clene's annual other inventories declined from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($-0.00 Mil) but then increased from Dec. 2022 ($-0.00 Mil) to Dec. 2023 ($0.00 Mil).


Clene Inventories, Other Historical Data

The historical data trend for Clene's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clene Inventories, Other Chart

Clene Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Other
0.03 - - - -

Clene Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 - - - -

Clene Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.


Clene (CLNNW) Business Description

Traded in Other Exchanges
Address
6550 South Millrock Drive, Suite G50, Salt Lake City, UT, USA, 84121
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. Its reportable segments: (1) the development and commercialization of novel clean-surfaced nanotechnology therapeutics (Drugs, and (2) the development and commercialization of dietary supplements (Supplements).